FindTrial
Sign In

A study to evaluate the usefulness of contrast medium 'Sonazoid; Perflubutane' in EUS diagnosis for pancreaticobiliary tumors.

A study to evaluate the usefulness of contrast medium 'Sonazoid; Perflubutane' in EUS diagnosis for pancreaticobiliary tumors. - Usefulness of contrast medium Sonazoid in EUS diagnosis for pancreaticobiliary tumors.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020395
Enrollment
100
Registered
2016-01-04
Start date
2016-01-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreaticobiliary neoplastic lesions that require EUS

Interventions

Sonazoid
Perflubutane suspension 0.015ml/kg

Sponsors

Div. of Gastroenterology and Hepatology, Dept. of Internal Medicine. Kansai Medical University Hirakata Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with pancreaticobiliary neoplastic lesions that require EUS.

Exclusion criteria

Exclusion criteria: Cases under 20 years old Cases without written informed consent Cases with allergy for Sonazoid; Perflubutane Cases with possibility of pregnant Cases considered ineligible for this study

Design outcomes

Primary

MeasureTime frame
final diagnostic performance, pathological diagnostic accuracy—

Countries

Japan

Contacts

Public ContactMakoto Takaoka

Kansai Medical University Div. of Gastroenterology and Hepatology, Dept. of Internal Medicine.

kenkyu@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026